This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Contraception and trophoblastic tumours

Authoring team

Contraception and hormone replacement therapy:

  • the combined oral contraceptive pill and hormone replacement therapy are safe to use after hCG levels have reverted to normal
  • the combined oral contraceptive pill, if taken while hCG levels are raised, may increase the need for treatment. However, it can be used safely after the hCG levels have returned to normal
  • other forms of hormonal contraception do not appear to be linked to an increased need for treatment (1). However the primary care clinician should seek expert guidance on when other forms of hormonal contraception should be used
    • the guidance from a specialist centre is that ALL forms of hormonal contraception should be avoided until hCG levels have returned to normal (2)
  • the small potential risk of using emergency hormonal contraception, in women with raised hCG levels, is outweighed by the potential risk of pregnancy to the woman
  • hormone replacement therapy may be used safely once hCG levels have returned to normal.

Reference:

  1. Royal College of Obstetricians and Gynaecologists (February 2004). Guideline No. 38 - The Management of gestational trophoblastic neoplasia.
  2. Personal email communication (9/10/06). Delia Short, Service Manager / Co-ordinator, Trophoblastic Tumour Screening & Treatment Centre, Department of Medical Oncology, Charing Cross Hospital, Hammersmith

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.